Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Covista Inc. (CVSA)
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-11-04
$112.96-9.04%
Close 2026-11-05 · 1-day change
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.01 → 10.11 EPS · FY ending Jun 30, 2028 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CVSA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS at or above $8.05 in FY 2026 | The company beat Q3 earnings with EPS of $1.98, 15% above estimates. | Broken | Adjusted EPS falls below $7.9 in FY 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented education business with a healthcare expansion angle, supported by robust earnings quality. The long-term thesis is intact, though volatile management signals, high risk, and a recent earnings miss make execution a key concern.
The valuation evidence points to CVSA being cheap versus peers, with expectations below the model’s baseline. The priced-in tag is justified and fragility is low, but these signals do not remove the risk that weak results or guidance could change expectations.
Near-term results show mixed signals: third-quarter revenue and enrollment grew, and fiscal 2027 guidance was raised, but the October 29 earnings miss sharply reduced company momentum and composite insight. Walden expanded with new programs and campus openings, while the employer partnership pipeline also advanced; the next call’s guidance remains an important near-term test.
The multi-year view depends on continued enrollment and revenue growth, expansion in healthcare programs, and progress in employer partnerships. Near term, a guidance cut would be a meaningful setback, while results and guidance from sector peers LAUR, LOPE, and LRN could either sustain or weaken the sector backdrop.
For the next one to three years, CVSA has tangible growth initiatives and a valuation that appears cheap versus peers, but recent earnings weakness and high execution risk leave the thesis dependent on renewed operating consistency. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating income rose to $111 million in 2026-Q2, showing better efficiency. |
| Intact |
| Operating income falls below $90 million in any quarter |
Operating income: $98.027M FY2027-Q1; GAAP. Published target: >=111.1 million USD. The stored target says 2026-Q2; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Oct 29, 202698,027,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue at or above $1.93 billion in FY 2026 | A primary condition in Covista Inc.'s published investment case. The stated target is >=1930 million USD. | Intact | Revenue falls below $1.92 billion in FY 2026 | Revenue: $511.534M FY2027-Q1; GAAP. Published target: >=1930 million USD. Annual target cannot be compared with a quarterly or TTM observation. Oct 29, 2026511,534,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$9.96 → $10.11 · observed estimates
$2.23B → $2.23B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-25 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-26 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-27 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-28 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-29 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-30 | $9.96 | $2,231,938,000 | 1 / 2 |
| 2026-07-31 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-01 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-02 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-03 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-04 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-05 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-06 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-07 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-08 | $9.96 | $2,232,221,500 | 2 / 2 |
| 2026-08-09 | $10.01 | $2,234,101,670 | 3 / 3 |
| 2026-08-10 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-11 | $10.01 | $2,234,101,670 | 3 / 3 |
| 2026-08-12 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-13 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-14 | $9.91 | $2,238,292,000 | 1 / 2 |
| 2026-08-15 | $9.91 | $2,238,292,000 | 2 / 3 |
| 2026-08-16 | $9.91 | $2,238,292,000 | 2 / 3 |
| 2026-08-17 | $9.91 | $2,238,292,000 | 2 / 3 |
| 2026-08-18 | $9.91 | $2,238,292,000 | 2 / 3 |
| 2026-08-19 | $9.91 | $2,238,292,000 | 2 / 3 |
| 2026-08-20 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-21 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-22 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-23 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-24 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-25 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-26 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-27 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-28 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-29 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-30 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-08-31 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-09-01 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-09-02 | $10.01 | $2,223,475,000 | 2 / 3 |
| 2026-09-03 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-04 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-05 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-06 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-07 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-08 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-09 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-10 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-11 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-12 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-13 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-14 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-15 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-16 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-17 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-18 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-19 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-20 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-21 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-22 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-23 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-24 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-25 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-26 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-27 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-28 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-29 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-09-30 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-01 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-02 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-03 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-04 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-05 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-06 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-07 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-08 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-09 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-10 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-11 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-12 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-13 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-14 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-15 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-16 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-17 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-18 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-19 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-20 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-21 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-22 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-23 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-24 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-25 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-26 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-27 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-28 | $10.01 | $2,223,475,000 | 3 / 3 |
| 2026-10-29 | $10.01 | $2,222,425,000 | 3 / 3 |
| 2026-10-30 | $10.01 | $2,222,425,000 | 3 / 3 |
| 2026-10-31 | $10.09 | $2,227,125,000 | 3 / 3 |
| 2026-11-01 | $10.09 | $2,227,125,000 | 2 / 3 |
| 2026-11-02 | $10.09 | $2,227,125,000 | 2 / 3 |
| 2026-11-03 | $10.11 | $2,227,118,750 | 3 / 3 |
| 2026-11-04 | $10.11 | $2,227,118,750 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.